宝莱特：独立董事 2023 年度述职报告（冉茂良） 广东宝莱特医用科技股份有限公司 独立董事 2023 年度述职报告 各位董事、各位股东： 本人作为广东宝莱特医用科技股份有限公司（以下简称"公司"）的独立董 事，在 2023 年度严格按照《公司法》《证券法》《上市公司治理准则》《上市 公司独立董事管理办法》《深圳证券交易所创业板股票上市规则》《深圳证券交 易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》等相关法律法 规和《公司章程》《独立董事工作制度》等公司相关的规定和要求，忠实履行独 立董事的职责，充分发挥独立董事独立性和专业性的作用，维护了全体股东尤其 是中小股东的合法权益。现就本人 2023 年度担任独立董事期间履行独立董事职 责情况向各位股东汇报如下： 一、2023 年度出席公司董事会和股东大会情况 公司 2023 年度共召开的 9 次董事会，2 次股东大会。本人在 2023 年度参加 了 9 次董事会会议，2 次股东大会。以上会议本人均亲自出席，无委托其他独立 董事或委员代为出席会议或代为表决的情形。本人对提交董事会、股东大会、专 门委员会的议案均认真审议，与相关人员充分沟通，积极讨论 ...

宝莱特：独立董事 2023 年度述职报告（杨振新） 广东宝莱特医用科技股份有限公司 独立董事 2023 年度述职报告 各位董事、各位股东： 本人作为广东宝莱特医用科技股份有限公司（以下简称"公司"）的独立董 事，根据《公司法》《证券法》《上市公司治理准则》《上市公司独立董事管理 办法》等有关法律法规以及《公司章程》《独立董事工作制度》等公司制度的规 定，在 2023 年度工作中， 竭诚履行独立董事的职责，充分发挥独立董事的独立 性和专业性作用，勤勉尽责，积极出席相关会议，认真审议董事会各项议案，对 公司重大事项发表了独立意见，充分发挥了独立董事及各专业委员会的作用及各 自的专业优势，积极关注和参与研究公司的发展，切实维护了公司和股东特别是 中小股东的利益。现就本人 2023 年度担任独立董事期间履行独立董事职责情况 向各位股东汇报如下： 一、出席公司董事会和股东大会情况 公司 2023 年度共召开的 9 次董事会，2 次股东大会。在本人 2023 年度任期 内，参加了 9 次董事会，2 次股东大会。任职期间本人严格按照有关法律法规的 要求，勤勉履行独立董事的职责，对公司提交董事会审议的各项议案及相关事项 均进 ...

广东宝莱特医用科技股份有限公司 审计报告 大华审字[2024]0011004608 号 大 华 会 计 师 事 务 所 (特 殊 普 通 合 伙 ) Da Hua Certified Public Accountants（Special General Partnership） 广东宝莱特医用科技股份有限公司 审计报告及财务报表 （2023 年 1 月 1 日至 2023 年 12 月 31 日止） | | 目 | 录 | 页 次 | | --- | --- | --- | --- | | 一、 | 审计报告 | | 1-7 | | 二、 | 已审财务报表 | | | | | 合并资产负债表 | | 1-2 | | | 合并利润表 | | 3 | | | 合并现金流量表 | | 4 | | | 合并股东权益变动表 | | 5-6 | | | 母公司资产负债表 | | 7-8 | | | 母公司利润表 | | 9 | | | 母公司现金流量表 | | 10 | | | 母公司股东权益变动表 | | 11-12 | | | 财务报表附注 | | 1-133 | 广东宝莱特医用科技股份有限公司全体股东： 一、审计意 ...

债券代码：123065 债券简称：宝莱转债 证券代码：300246 证券简称：宝莱特 公告编号：2024-037 广东宝莱特医用科技股份有限公司 关于召开 2023 年年度股东大会的通知 本公司及董事会全体成员保证公告内容真实、准确、完整，不存在虚假记载、 误导性陈述或重大遗漏。 一、召开会议的基本情况 1、股东大会届次：2023 年年度股东大会 2、会议召集人：广东宝莱特医用科技股份有限公司董事会 3、会议召开的合法、合规性：经广东宝莱特医用科技股份有限公司（以下 简称"公司"）第八届董事会第十四次会议审议通过，决定召开 2023 年年度股 东大会，召集程序符合《中华人民共和国公司法》和《公司章程》等的规定。 4、会议召开日期和时间： （1）现场会议召开时间：2024 年 5 月 20 日（星期一）下午 14:40 （2）网络投票时间如下： 通过深圳证券交易所交易系统进行网络投票的具体时间为：2024 年 5 月 20 日 9:15-9:25，9:30-11:30，13:00-15:00； 通过深圳证券交易所互联网投票系统（http://wltp.cninfo.com.cn）投票的具体 时间为：2024 年 ...

大华会计师事务所（特殊普通合伙）（以下简称"大华会计师事务所"）成立 于 2012 年 2 月（由大华会计师事务所有限公司转制为特殊普通合伙企业），注 册地址为北京市海淀区西四环中路16号院7号楼1101，首席合伙人为梁春先生， 拥有财政部颁发的会计师事务所执业证书，是我国最早从事证券业务的会计师事 务所以及首批获得 H 股企业审计资格的事务所之一，具有近 30 年的证券业务从 业经验。截至 2023 年 12 月 31 日，大华会计师事务所从业人员总数 7,781 人， 其中合伙人 270 人，注册会计师 1471 人；注册会计师中，超过 1000 人签署过证 券服务业务审计报告。 （二）聘任会计师事务所履行的程序 公司第八届董事会第四次会议及 2022 年年度股东大会审议通过了《关于聘 任公司 2023 年度财务审计机构的议案》，董事会同意续聘大华会计师事务所（特 殊普通合伙）为公司 2023 年度财务审计机构，聘期一年。大华会计师事务所（特 殊普通合伙）具备证券、期货相关业务执业资格，具备多年为上市公司提供审计 服务的经验与能力。在担任公司 2022 年度审计机构期间，大华会所恪尽职守， 遵循独立、客观 ...

Financial Performance - In 2023, the company recorded a significant decline in net profit attributable to shareholders, primarily due to impairment losses totaling RMB 116.58 million[4]. - The company's operating revenue for 2023 was CNY 1,194,001,129.61, representing a year-on-year increase of 0.87% compared to CNY 1,183,699,680.25 in 2022[24]. - The net profit attributable to shareholders for 2023 was a loss of CNY 65,185,130.69, a significant decline of 394.52% from a profit of CNY 21,997,981.33 in 2022[24]. - The net cash flow from operating activities decreased by 8.30% to CNY 129,047,347.24 in 2023, down from CNY 140,721,997.37 in 2022[24]. - The total equity attributable to shareholders decreased by 7.43% to CNY 1,310,894,066.37 at the end of 2023 from CNY 1,416,280,945.50 at the end of 2022[24]. - The company indicated uncertainty regarding its ability to continue as a going concern, as reflected in the audit report for the most recent year[25]. - The company will not distribute cash dividends, issue bonus shares, or increase capital from reserves[7]. - The company reported a significant increase in non-operating losses, with a total of CNY 16,318,188.91 in 2023 compared to CNY 28,653,932.63 in 2022[31]. Market Trends and Opportunities - The medical device industry remains prosperous, with no signs of overcapacity or continuous decline[4]. - The global medical device market size reached $552.8 billion in 2022, with a year-on-year growth of 5.9%[35]. - China's medical device market size exceeded ¥900 billion in 2022, projected to surpass ¥2.2 trillion by 2030, becoming the largest in the world[36]. - The blood purification industry is experiencing a clear growth trend, supported by government policies and increasing market demand for innovative products and technologies[44]. - The company plans to enhance operational management and leverage opportunities in domestic medical device replacement and hospital upgrades[6]. - The government has implemented policies to enhance the construction of medical resources, including the establishment of independent hemodialysis centers in major cities[41]. Research and Development - Research and development investment amounted to 93.35 million yuan, a year-on-year increase of 3%[58]. - The company and its subsidiaries held a total of 381 patents, with 83 new patents added during the reporting period[60]. - The company has established a comprehensive layout in the blood purification equipment and consumables sector, with nine consumable bases and three channel platforms[45]. - The company emphasizes R&D, maintaining a collaborative development process to ensure the conversion of technological innovations into marketable products[53]. - The company is committed to ongoing research and development of new medical technologies to meet market demands and improve healthcare outcomes[1]. Product Development and Innovation - The company aims to build a kidney medical ecosystem through a full industry chain, regional coverage, specialized operations, and lean management[45]. - The company is focused on expanding its product line in the blood purification sector, which is expected to enhance market competitiveness[96]. - The company has launched several new products, including the S200 enteral nutrition pump and various models of infusion and injection pumps[62]. - The company is exploring strategic acquisitions to enhance its product portfolio and expand its technological capabilities in the healthcare sector[61]. - The company aims to enhance its technological capabilities with the introduction of new software systems for its medical devices[62]. Corporate Governance and Management - The company has established a layered governance structure involving the shareholders' meeting, board of directors, supervisory board, and management[162]. - The company has implemented strict information disclosure practices, ensuring timely and accurate communication with investors[165]. - The board of directors consists of 9 members, including 3 independent directors, and has held 9 meetings during the reporting period[165]. - The company has established a performance evaluation and incentive system for its directors, supervisors, and senior management, ensuring that compensation is linked to actual performance[166]. - The company is committed to improving its corporate governance structure in compliance with relevant laws and regulations[162]. Strategic Outlook - Future outlook includes plans to expand market presence in Southeast Asia, targeting a 15% increase in market share by 2025[61]. - The company has set a revenue guidance of approximately $150 million for the next fiscal year, representing a 20% increase compared to the previous year[61]. - The company plans to adjust the internal investment structure for the marketing network and information technology construction projects[126]. - The company aims to enhance operational efficiency by optimizing organizational structure and improving internal control systems, with a focus on cost control and risk management[143]. - The company is actively pursuing market expansion strategies to increase its footprint in the medical technology industry[19][22].

Revenue and Profit - Revenue for Q1 2024 was CNY 266.86 million, a decrease of 22.55% compared to CNY 344.57 million in the same period last year[5] - Net profit attributable to shareholders was CNY 3.63 million, down 86.65% from CNY 27.16 million year-on-year[5] - The company reported a significant decrease in operating profit, which fell by 85.47% to CNY 5.23 million from CNY 36.00 million year-on-year[9] - The total profit decreased by 84.11% to CNY 5.10 million compared to CNY 32.09 million in the same period last year[9] - Basic and diluted earnings per share were CNY 0.0137, a decline of 91.13% from CNY 0.1545 in the same period last year[5] - Net profit for Q1 2024 was ¥4,430,173.89, a decline of 84.4% from ¥28,305,836.21 in Q1 2023[22] - The company reported a total comprehensive income of ¥3,974,456.23 for Q1 2024, compared to ¥28,710,677.12 in Q1 2023[22] Cash Flow - The net cash flow from operating activities improved by 61.38%, reaching -CNY 24.71 million compared to -CNY 63.98 million in the previous year[5] - The net cash flow from operating activities decreased by 39,272,475.45, a reduction of 61.38% compared to the previous period, primarily due to decreased procurement payments[10] - The cash received from investment recoveries was 66,900,000.00, marking a 100.00% increase, attributed to the recovery of principal from financial products[10] - The cash flow from investment activities totaled 74,391,457.29, an increase of 247,871.52%, mainly due to the recovery of principal from financial products[10] - The net cash flow from financing activities increased by 54,307,615.87, a rise of 122.56%, primarily due to increased bank loan repayments[10] - The company reported a cash increase of CNY 86,453,209.03 in Q1 2024, compared to CNY 32,130,753.01 in Q1 2023, marking a significant rise of approximately 169.9%[25] Assets and Liabilities - Total assets increased by 1.61% to CNY 2.58 billion from CNY 2.53 billion at the end of the previous year[5] - The company reported a total asset of CNY 2,575,176,425.17 as of March 31, 2024, an increase from CNY 2,534,398,019.03 at the beginning of the period, reflecting a growth of approximately 1.6%[17] - The total liabilities amounted to CNY 1,189,312,347.03, up from CNY 1,145,452,995.95, indicating an increase of approximately 3.8%[19] - The company’s long-term borrowings increased by 63.96% to CNY 144.84 million, reflecting increased bank loans during the reporting period[9] - The company’s long-term borrowings increased to CNY 144,840,000.00 from CNY 88,340,000.00, showing a significant rise of approximately 63.8%[19] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 20,648[12] - The largest shareholder, Yan Jinyuan, holds 26.72% of the shares, totaling 70,705,185 shares, with 7,980,000 shares pledged[13] - The company has repurchased a total of 1,073,550 shares, accounting for 0.4058% of the total share capital, with a total expenditure of between CNY 20 million and CNY 30 million planned for the buyback[16] - The company plans to implement an employee stock ownership plan or equity incentive through the repurchased shares[16] Expenses - Sales expenses decreased by 30.38% to CNY 34.35 million, attributed to improved efficiency in the sales department[9] - Research and development expenses decreased to ¥18,430,075.31, down 25.7% from ¥24,786,031.00 in the previous year[21] Legal Matters - The company is actively monitoring a patent infringement lawsuit with Shenzhen Mindray Bio-Medical Electronics Co., Ltd., and will take necessary measures to protect its rights[15] Accounting Standards - The company did not undergo an audit for the Q1 2024 report[26] - The company has adopted new accounting standards starting from 2024, impacting the financial statements[26]

证券代码：300246 证券简称：宝莱特 公告编号：2024-034 债券代码：123065 债券简称：宝莱转债 广东宝莱特医用科技股份有限公司 关于为子公司提供担保及解除担保的公告 本公司及董事会全体成员保证公告内容真实、准确、完整，不存在虚假记载、 误导性陈述或重大遗漏。 一、担保概况 广东宝莱特医用科技股份有限公司（以下简称"公司"）于 2024 年 4 月 24 日 召开了第八届董事会第十四次会议，审议通过了《关于为子公司提供担保的议 案》，为保证公司子公司深圳市宝原医疗器械有限公司（以下简称"深圳宝原"）、 珠海市宝瑞医疗器械有限公司（以下简称"珠海宝瑞"）、武汉柯瑞迪医疗用品 有限公司（以下简称"柯瑞迪"）生产经营的资金需求，降低成本，公司董事会 同意深圳宝原、珠海宝瑞、柯瑞迪分别在以下金融机构申请授信额度，公司为上 述融资提供连带责任担保，具体担保范围包括但不限于本金以及利息、罚息、复 息、违约金、迟延履行金、保理费用、实现抵押权和债权的费用和其他相关费用， 在额度内可循环使用，担保期限自本次董事会审议通过之日起至 2026 年 4 月 30 日，申请的授信及担保额度最终以银行实际签署的协议为准 ...

宝莱特：内部控制自我评价报告 广东宝莱特医用科技股份有限公司 内部控制自我评价报告 广东宝莱特医用科技股份有限公司全体股东： 根据《企业内部控制基本规范》及其配套指引的规定和其他内部控制监管要 求（以下简称"企业内部控制规范体系"），结合广东宝莱特医用科技股份有限公 司（以下简称"公司"）内部控制制度和评价办法，在内部控制日常监督和专项监 督的基础上，我们对公司2023年12月31日（以下简称"内部控制评价报告基准日"） 的内部控制的有效性进行了自我评价。 一、重要声明 按照企业内部控制规范体系的规定，建立健全和有效实施内部控制，评价其 有效性，并如实披露内部控制评价报告是公司董事会的责任。监事会对董事会建 立和实施内部控制进行监督。经营层负责组织领导企业内部控制的日常运行。公 司董事会、监事会及董事、监事、高级管理人员保证本报告内容不存在任何虚假 记载、误导性陈述或重大遗漏，并对报告内容的真实性、准确性和完整性承担个 别及连带法律责任。 公司内部控制的目标是合理保证经营管理合法合规、资产安全、财务报告及 相关信息真实完整，提高经营效率和效果，促进实现发展战略。由于内部控制存 在的固有局限性，故仅能为实现上述 ...

广东宝莱特医用科技股份有限公司 会计师事务所选聘制度 广东宝莱特医用科技股份有限公司 会计师事务所选聘制度 第一章 总则 第一条 为进一步规范广东宝莱特医用科技股份有限公司（以下简称"公 司"）选聘会计师事务所的相关行为，提高财务信息质量，根据有关法律法规以 及《广东宝莱特医用科技股份有限公司章程》（以下简称《公司章程》）的有关 规定，结合公司实际情况，制定本制度。 第二条 本制度所称选聘会计师事务所，是指公司根据有关法律法规要求， 聘任会计师事务所对本公司财务会计报告发表审计意见、出具审计报告及内部控 制报告的行为。公司下属全资或控股子公司不再单独选聘会计师事务所。公司聘 任会计师事务所从事其他法定审计业务的，可以参照本制度执行。 （六）定期（至少每年）向董事会提交对受聘会计师事务所的履职情况评估 报告及审计委员会履行监督职责情况报告； -1- 广东宝莱特医用科技股份有限公司 会计师事务所选聘制度 第三条 公司选聘会计师事务所，应当经董事会审计委员会（以下简称"审 计委员会"）审议同意后，提交董事会审议，并由股东大会决定。公司不得在股 东大会决定前委托会计师事务所开展工作。 第四条 审计委员会负责选聘会计师 ...